Clinical Trial Update: The Nordic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumtoxin A Dual Therapy Compared to CGRP mAbs Monotherapy [Phase 3]

View source ↗

Summary

A Phase 3 trial at Oslo University Hospital is evaluating dual therapy with a CGRP monoclonal antibody plus OnabotulinumtoxinA versus CGRP mAb monotherapy for c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• CGRP monoclonal antibody
• OnabotulinumtoxinA (botulinum toxin type A)

Snippet

Sponsor: Oslo University Hospital | Conditions: Migraine, Chronic Migraine Headache | Phase 3 | Status: RECRUITING